<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251732</url>
  </required_header>
  <id_info>
    <org_study_id>Merit Review Study</org_study_id>
    <nct_id>NCT00251732</nct_id>
  </id_info>
  <brief_title>Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)</brief_title>
  <official_title>Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Arizona VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica N.V., Belgium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Arizona VA Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the role of pain modulation in GERD patients
      who fail to obtain clinical relief with standard dose (once daily) PPI. The study will
      compare the efficacy of 1) standard dose PPI plus low-dose tricyclic antidepressant (TCA) to,
      2) double dose PPI to, 3) standard dose PPI and placebo to determine the relative symptom
      resolution and health related quality of life in GERD patients who fail standard dose PPI and
      are randomly assigned to one of these three groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the role of pain modulation in gastroesophageal reflux disease(GERD)patients who
      fail to obtain clinical relief with standard dose (once daily) proton pump inhibitor(PPI).
      The study will compare the efficacy; of 1)standard dose PPI plus low-dose tricyclic
      antidepressant (TCA) to, 2) double dose PPI to, 3) standard dose PPI and placebo to determine
      the relative symptom resolution and health related quality of life in GERD patients who fail
      standard dose PPI and are randomly assigned to one of these three groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom control after 6 weeks of treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>To measure the outcome after 6 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of drop-outs due to poor symptom control</measure>
    <time_frame>6 weeks</time_frame>
    <description>To measure the number of drop-outs due to poor symptom control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of antacid consumption</measure>
    <time_frame>6 weeks</time_frame>
    <description>To measure the level of antacid consumption due to poor symptom control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>6 weeks</time_frame>
    <description>To improve quality of life with GERD symptom control.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Standard dose (PPI) plus low dose TCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose PPI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double dose proton pump inhibitor plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose PPI plus placebo x 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dose (once daily) PPI plus low-dose antidepressant</intervention_name>
    <description>20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)</description>
    <arm_group_label>Standard dose (PPI) plus low dose TCA</arm_group_label>
    <other_name>Aciphex-PPI</other_name>
    <other_name>Nortriptyline-TCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Double dose PPI plus evening placebo</intervention_name>
    <description>20 mg. twice daily with a placebo</description>
    <arm_group_label>Double dose PPI</arm_group_label>
    <other_name>Aciphex-PPI, rabeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole , placebo, placebo</intervention_name>
    <description>20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime</description>
    <arm_group_label>Standard dose PPI plus placebo x 2</arm_group_label>
    <other_name>Aciphex-rabeprazole (PPI)</other_name>
    <other_name>Nortriptyline-low-dose tricyclic antidepressant (TCA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Ages 18 to 75

          -  At least two episodes of heartburn per week while on PPI once daily

          -  Able to communicate with the investigator and comply with the requirements of the
             study

          -  Subjects who give written informed consent after being given a full description of the
             study.

        Exclusion Criteria:

          -  Known allergy or intolerance to TCA

          -  Use of antidepressant or a diagnosis of depression

          -  History of serious arrhythmia or use of anti-arrhythmics

          -  History of seizures

          -  Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital,
             renal, gastrointestinal, hepatic, hematologic, endocrine, neurologic or psychiatric.

          -  Evidence or history of drug abuse within the past 6 months

          -  Erosive esophagitis, esophageal ulceration, peptic stricture, Barret's esophagus, or
             adenocarcinoma of the esophagus on endoscopy.

          -  History of esophagogastric surgery

          -  Gastric or duodenal lesions (ulcer, tumor, etc)

          -  Women who are pregnant or of childbearing age who are not on contraception

          -  Patients who are unwilling or unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronnie Fass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAVAHCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>August 18, 2010</last_update_submitted>
  <last_update_submitted_qc>August 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ronnie Fass MD</name_title>
    <organization>SArizonaVAHCS</organization>
  </responsible_party>
  <keyword>acid reflux studies</keyword>
  <keyword>efficacy of PPI therapy</keyword>
  <keyword>failing PPI therapy</keyword>
  <keyword>GERD</keyword>
  <keyword>Acid Reflux Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Antidepressive Agents, Tricyclic</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

